{"nct_id":"NCT03051256","title":"Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD","status":"COMPLETED","status_verified_date":"2023-10","start_date":"2018-05-11","start_date_type":"ACTUAL","primary_completion_date":"2019-07-30","primary_completion_date_type":"ACTUAL","completion_date":"2019-09-30","completion_date_type":"ACTUAL","phases":["PHASE2"],"tickers":["RLMD"]}